By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
2026 will be the year NASA astronauts fly around the moon again — if all goes to plan - 275% of Arab Israelis support Arab party joining government coalition post-war, survey reveals
- 3The most effective method to Plan an Incineration Administration: A Bit by bit Guide.
- 4Manual for Picking Coastline Travel
- 5Denny's is shutting down restaurants around the country. What's behind the closures?
- Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Finding Your Motivation: Moves toward a Satisfying Life
- The most effective method to Explore Moral Situations in Brain research with Your Certification
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- West Antarctica’s history of rapid melting foretells sudden shifts in continent’s ‘catastrophic’ geology
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Discovering a sense of harmony: Individual Accounts of Reflection and Care
- Vote In favor of Your Number one Kind Of Food Conveyance Administration
